دورية أكاديمية
أعرض في EDS

Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands.

التفاصيل البيبلوغرافية
العنوان: Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands.
المؤلفون: Cavalieri S; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy. Electronic address: stefano.cavalieri@istitutotumori.mi.it., Mariani L; Clinical Epidemiology and Trial Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy., Vander Poorten V; Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven and Department of Oncology, Section Head and Neck Oncology, KU Leuven, Leuven, Belgium., Van Breda L; Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven and Department of Oncology, Section Head and Neck Oncology, KU Leuven, Leuven, Belgium., Cau MC; Medical Oncology Unit, Azienda Ospedaliera Brotzu, Cagliari, Italy., Lo Vullo S; Clinical Epidemiology and Trial Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy., Alfieri S; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy., Resteghini C; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy., Bergamini C; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy., Orlandi E; Radiotherapy 1-2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy., Calareso G; Radiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy., Clement P; Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium., Hauben E; Department of Pathology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium., Platini F; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy., Bossi P; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy., Licitra L; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Italy., Locati LD; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.
المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Sep; Vol. 136, pp. 35-42. Date of Electronic Publication: 2020 Jul 03.
نوع المنشور: Journal Article; Validation Study
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Elsevier Science Ltd
Original Publication: Oxford ; New York : Pergamon Press, c1990-
مواضيع طبية MeSH: Nomograms*, Carcinoma, Adenoid Cystic/*diagnosis , Salivary Gland Neoplasms/*diagnosis, Adult ; Aged ; Belgium/epidemiology ; Carcinoma, Adenoid Cystic/mortality ; Carcinoma, Adenoid Cystic/pathology ; Carcinoma, Adenoid Cystic/therapy ; Cohort Studies ; Female ; Humans ; Italy/epidemiology ; Male ; Middle Aged ; Neoplasm Metastasis ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Salivary Gland Neoplasms/mortality ; Salivary Gland Neoplasms/pathology ; Salivary Gland Neoplasms/therapy ; Survival Analysis
مستخلص: Background: Distant metastases in adenoid cystic carcinoma (ACC) are common. There is no consensus on the management of metastatic disease because no therapeutic approach has demonstrated improvement in overall survival (OS) and because of prolonged life expectancy. The aim of this study is to build and validate a prognostic nomogram for metastatic ACC patients.
Methods: The study end-point was OS, measured from the date of first metastatic presentation to death/last follow-up. A retrospective analysis including metastatic ACC patients was performed to build the prognostic nomogram at the INT (Milan, Italy). The model was validated on an independent cohort of patients with similar characteristics treated at Leuven (Belgium). Outcome data and covariates were modelled by resorting to a random forest method. This machine-learning approach was used to guide and benchmark the subsequent use of more conventional modelling methods. Cox model performance was assessed in terms of discrimination (Harrell's c-index).
Results: Two hundred ninety-eight patients with metastatic ACC (testing set 259 INT, validation set 39 Leuven) were studied. Akaike Information Criterion-based backward selection yielded a 5-factor model showing a bias-corrected c-index of 0.730. Five independent prognostic factors were found: gender, disease-free interval and presence of lung, liver or bone metastases. Nomogram discrimination in the validation series was c = 0.701.
Conclusion: This retrospective analysis allowed the building of an externally validated prognostic nomogram. This tool might help clinicians to discriminate patients requiring prompt management from who can benefit from a 'watchful waiting'. In addition, the nomogram might be useful to stratify patients in clinical trials.
Competing Interests: Conflict of interest statement L.D.L. declares grant and other financial relationship with Biogen, Eisai, Ipsen, Lilly, Merck Serono, MSD and BMS. P.B. is on advisory board of Merck, Sanofi, Merck Sharp & Dohme, Sun Pharma, Angelini, AstraZeneca, Bristol-Myers Squibb, Helsinn and received conference honoraria from Bristol-Myers Squibb, Kyowa Hakko Kirin, Angelini, Sanofi, Roche, GSK. L.L. has received funding (for her Institution) for clinical studies and research from AstraZeneca, Boehringer Ingelheim, Eisai, Merck Serono, MSD, Novartis and Roche; has received compensation for service as a consultant/advisor and/or for lectures from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Debiopharm, Eisai, Merck Serono, MSD, Novartis, Roche and Sobi and she has received travel coverage for medical meetings from Bayer, Bristol-Myers Squibb, Debiopharm, Merck Serono, MSD and Sobi. The remaining authors declare no conflict of interest.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
فهرسة مساهمة: Keywords: Adenoid cystic carcinoma; Nomogram; Prognosis; Salivary gland cancer
تواريخ الأحداث: Date Created: 20200707 Date Completed: 20210106 Latest Revision: 20210106
رمز التحديث: 20231215
DOI: 10.1016/j.ejca.2020.05.013
PMID: 32629365
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-0852
DOI:10.1016/j.ejca.2020.05.013